DeepMed Research

CHIESI FARMACEUTICI S.P.A.

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1935-01-01

Employees: -

Market Cap: -

Website: http://www.chiesigroup.com

Clinical Trials

PK of BDP/FF/GB Single-inhaler Triple Therapy in Japanese vs. Caucasians

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Drug: Placebo
Drug: Therapeutic Dose 2
Drug: Supra-therapeutic Dose
Drug: Therapeutic Dose 1

First Posted Date: 2019-03-01

Last Posted Date: 2021-10-22

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 32

Registration Number: NCT03859414

Locations: 🇬🇧
Richmond Pharmacology Ltd, London, Tooting, United Kingdom

Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients

Phase 1

Terminated

Conditions: Chronic Obstructive Pulmonary Disease
Asthma

Interventions: Drug: Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide

First Posted Date: 2019-01-07

Last Posted Date: 2022-05-06

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 19

Registration Number: NCT03795350

Locations: 🇬🇧
Simbec Research Ltd, Merthyr Tydfil, United Kingdom

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Phase 3

Active, not recruiting

Conditions: Fabry Disease

Interventions: Drug: pegunigalsidase alfa

First Posted Date: 2018-08-03

Last Posted Date: 2024-10-08

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 29

Registration Number: NCT03614234

Locations: 🇺🇸
Renal Disease Research Institute, LLC, Dallas, Texas, United States
🇩🇰
Medical Endocrinology PE 2132, Rigshospitalet, Copenhagen, Denmark
🇺🇸
UAB Medicine, Birmingham, Alabama, United States

and more 11 locations

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Phase 3

Terminated

Conditions: Catheter Occlusion
Thrombosis

Interventions: Drug: Placebo
Drug: CUSA-081
Drug: Alteplase

First Posted Date: 2018-07-20

Last Posted Date: 2024-08-23

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 462

Registration Number: NCT03594175

Locations: 🇷🇴
Chiesi Invesitgational Site, Cluj-Napoca, Romania
🇺🇸
Einspahr, Topeka, Kansas, United States
🇪🇸
Chiesi Investigational Site, Sevilla, Spain

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: CHF 5993 DPI
Drug: CHF5993 pMDI
Drug: CHF 1535 pMDI
Drug: Placebo pMDI
Drug: Placebo DPI

First Posted Date: 2018-07-18

Last Posted Date: 2021-04-12

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 366

Registration Number: NCT03590379

Locations: 🇧🇬
Medical Center Convex EOOD, Sofia, Bulgaria

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Phase 3

Completed

Conditions: Fabry Disease

Interventions: Drug: pegunigalsidase alfa

First Posted Date: 2018-06-21

Last Posted Date: 2025-05-20

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 97

Registration Number: NCT03566017

Locations: 🇸🇮
General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia
🇺🇸
Infusion Associates, Grand Rapids, Michigan, United States
🇺🇸
Institute of Metabolic Disease, Dallas, Texas, United States

and more 27 locations

The Adherence of Immunosuppressive Therapy Including Tacrolimus Once-daily in Italian Kidney Transplant Recipients

Completed

Conditions: Kidney Transplant

First Posted Date: 2018-06-15

Last Posted Date: 2022-05-05

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 158

Registration Number: NCT03558373

Locations: 🇮🇹
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹
A.O.U. Consorziale Policlinico, Bari, Italy
🇮🇹
A.O.U. Policlinico S.Orsola Malpighi, Bologna, Italy

and more 9 locations

Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Foster 100/6mg NEXThaler
Drug: Foster 100/6mg pMDI

First Posted Date: 2018-03-05

Last Posted Date: 2023-11-28

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 494

Registration Number: NCT03453112

Locations: 🇨🇳
Chiesi Clinical Trial site 15670, Guizhou, China
🇨🇳
Chiesi Clinical Trial site 15641, Hefei, Anhui, China
🇨🇳
Chiesi clinical Trial site 15656, Guangzhou, Guangdong, China

and more 47 locations

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Phase 1

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease

Interventions: Drug: umeclidinium bromide and vilanterol trifenatate
Drug: Placebo CHF6366
Drug: CHF6366

First Posted Date: 2017-12-20

Last Posted Date: 2020-05-07

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 118

Registration Number: NCT03378648

Locations: 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom

Functional Respiratory Imaging Study (FRI)

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium

First Posted Date: 2017-08-31

Last Posted Date: 2020-03-04

Lead Sponsor: Chiesi Farmaceutici S.p.A.

Target Recruit Count: 20

Registration Number: NCT03268226

Locations: 🇭🇺
National Koranyi Institute for TB and Pulmonology, Budapest, Hungary
🇧🇪
Heilige Familie AZ, Reet, Belgium
🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy